Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.69 |
| ▸ | ITGAV | P06756 | 20/20 | 0.69 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14546828 | 1.00 | ITGB3 (0.69) | ITGB3ITGAVITGA2B | |
| SCHEMBL5561642 | 0.99 | ITGB3 (0.70) | ITGB3ITGAVITGA2B | |
| SCHEMBL5561128 | 0.91 | ITGB3 (0.60) | ITGB3ITGAVITGA2B | |
| SCHEMBL5567560 | 0.90 | ITGB3 (0.61) | ITGB3ITGAVITGA2B | |
| SCHEMBL5566167 | 0.86 | ITGB3 (0.61) | ITGB3ITGAVITGA2B | |
| SCHEMBL14547080 | 0.86 | ITGB3 (0.61) | ITGB3ITGAVITGA2B | |
| SCHEMBL5566170 | 0.86 | ITGB3 (0.61) | ITGB3ITGAVITGA2B | |
| SCHEMBL14547071 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL5560942 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2B | |
| SCHEMBL5560949 | 0.84 | ITGB3 (0.62) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1240161-B1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA GMBH (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-6762190-B2 | VITRONECTIN RECEPTOR ANTAGONISTS; SUPPRESSING OSTEOCLAST BONE RESORPTION; PREVENTING ANGIOGENESIS OR VASCULAR SMOOTH MUSCLE PROLIFERATION | AVENTIS PHARMA S.A. DEUTSCHLAND GMBH GENENTECH, INC. (DE) | 2004-07-13 | — | — | US | disclosed |
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | AVENTIS PHARMA S.A. DEUTSCHLAND GMBH (DE) | 2003-06-05 | — | — | US | disclosed |
| EP-1240161-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2002-09-18 | — | — | EP | disclosed |
| WO-2001044237-A1 | THIENYLALANINE DERIVATIVES AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-21 | — | — | WO | disclosed |
| EP-1108721-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | Aventis Pharma Deutschland GmbH (DE) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105080-A1 | Thienylalanine derivatives as inhibitors of cell adhesion | VCAM1, TEK, ADGRF1 | ITGB3 5/4885ITGAV 31/4885ITGA2B 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.